This is the category page. Below are all of the research programs that are associated with it
AML/MDS:
COG: AAML0431 – THE TREATMENT OF DOWN SYNDROME CHILDREN WITH ACUTE MYELOID LEUKEMIA (AML) AND MYELODYSPLASTIC SYNDROME (MDS) UNDER THE AGE OF 4 YEARS
(1_20090601_118)
This study is for children diagnosed with AML/MDS before the age of 4 years old that have Down syndrome. Down syndrome children on other studies appeared to have comparable degrees of toxicity except for significantly higher rates of mucositis and skin toxicity. On this study, Down syndrome participants will be treated with a total of six cycles of therapy, two cycles of intensification etoposide and continuous infusion of Ara-C. For this study the overall total cumulative dose of daunorubicin will be 240mg/m2, which is comparable to other studies.
